These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38636988)

  • 1. Bedaquiline, pretomanid and linezolid in multidrug-resistant and pre-extensively drug-resistant tuberculosis in refugees from Ukraine and Somalia in Germany.
    Trauth J; Kantelhardt V; Usenko B; Knipper M; Kuhns M; Friesen I; Herold S
    Eur Respir J; 2024 May; 63(5):. PubMed ID: 38636988
    [No Abstract]   [Full Text] [Related]  

  • 2. Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
    Li SY; Converse PJ; Betoudji F; Lee J; Mdluli K; Upton A; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0003523. PubMed ID: 36920217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ; Gibbert J; Wirth D; Diel R
    Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract]   [Full Text] [Related]  

  • 5. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response.
    Lange C; Kherabi Y; Guglielmetti L; Duarte R; Günther G;
    Clin Microbiol Infect; 2024 Sep; 30(9):1207-1208. PubMed ID: 38901496
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel drugs against tuberculosis: a clinician's perspective.
    Olaru ID; von Groote-Bidlingmaier F; Heyckendorf J; Yew WW; Lange C; Chang KC
    Eur Respir J; 2015 Apr; 45(4):1119-31. PubMed ID: 25431273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.
    Li S-Y; Tyagi S; Soni H; Betoudji F; Converse PJ; Mdluli K; Upton AM; Fotouhi N; Barros-Aguirre D; Ballell L; Jimenez-Navarro E; Nuermberger EL
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0156223. PubMed ID: 38376228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis.
    Labuda SM; Seaworth B; Dasgupta S; Goswami ND;
    Lancet Respir Med; 2024 Feb; 12(2):e5-e6. PubMed ID: 38043563
    [No Abstract]   [Full Text] [Related]  

  • 9. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.
    Almeida D; Li S-Y; Lee J; Hafkin B; Mdluli K; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0078923. PubMed ID: 37966090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
    Howell P; Upton C; Mvuna N; Olugbosi M
    BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34876446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
    Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
    BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
    Tadolini M; Lingtsang RD; Tiberi S; Enwerem M; D'Ambrosio L; Sadutshang TD; Centis R; Migliori GB
    Eur Respir J; 2016 Sep; 48(3):935-8. PubMed ID: 27288039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
    Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman.
    Jaspard M; Elefant-Amoura E; Melonio I; De Montgolfier I; Veziris N; Caumes E
    Emerg Infect Dis; 2017 Oct; 23(10):1731-2. PubMed ID: 28792382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bedaquiline plus delamanid for XDR tuberculosis.
    Lachâtre M; Rioux C; Le Dû D; Fréchet-Jachym M; Veziris N; Bouvet E; Yazdanpanah Y
    Lancet Infect Dis; 2016 Mar; 16(3):294. PubMed ID: 26973310
    [No Abstract]   [Full Text] [Related]  

  • 16. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
    Oelofse S; Esmail A; Diacon AH; Conradie F; Olayanju O; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Wills GH; Olugbosi M; Del Parigi A; Sun E; Calatroni A; Spigelman M; Dheda K
    Int J Tuberc Lung Dis; 2021 Jun; 25(6):453-460. PubMed ID: 34049607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Children Born to Pregnant Women With Drug-resistant Tuberculosis Treated With Novel Drugs in Khayelitsha, South Africa: A Report of Five Patients.
    Acquah R; Mohr-Holland E; Daniels J; Furin J; Loveday M; Mudaly V; Reuter A
    Pediatr Infect Dis J; 2021 May; 40(5):e191-e192. PubMed ID: 33847295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
    Conradie F; Bagdasaryan TR; Borisov S; Howell P; Mikiashvili L; Ngubane N; Samoilova A; Skornykova S; Tudor E; Variava E; Yablonskiy P; Everitt D; Wills GH; Sun E; Olugbosi M; Egizi E; Li M; Holsta A; Timm J; Bateson A; Crook AM; Fabiane SM; Hunt R; McHugh TD; Tweed CD; Foraida S; Mendel CM; Spigelman M;
    N Engl J Med; 2022 Sep; 387(9):810-823. PubMed ID: 36053506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis.
    Vasilyeva I; Mariandyshev A; Kazennyy B; Davidavičienė E; Lounis N; Keim S;
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31097518
    [No Abstract]   [Full Text] [Related]  

  • 20. Barriers to new drug development in respiratory disease.
    Brigden G; du Cros P; Wong S
    Eur Respir J; 2016 Jan; 47(1):356-7. PubMed ID: 26721975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.